FDA places Regulus' Hep C drug on clinical hold; shares dive

June 27, 2016 9:31 PM

11 0

Regulus Therapeutics Inc said the U.S. Food and Drug Administration placed on clinical hold the company's drug to treat chronic hepatitis C virus infection, sending its shares plunging 60 percent in extended trading.

The FDA initiated the clinical hold on the drug, RG-101, after Regulus reported a second serious adverse event of jaundice, the company said on Monday.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page